Aprecia Pharmaceuticals is proud to announce Owen Murray as its new Chief Executive Officer. With Murray at the helm, Aprecia is set to revolutionize the pharmaceutical industry with its cutting-edge 3D-Printed technologies. Murray will be responsible for advancing the company’s mission of creating innovative and accessible treatments for people around the world.
Owen’s diverse background in healthcare innovation and pharmaceutical commercialization is a major asset to Aprecia. With his specialized knowledge, Aprecia is primed to explore new growth opportunities, offering valuable partnerships and effective solutions for the betterment of patients globally. E. Thomas Arington, Aprecia’s Chairman, is confident that Owen’s expertise will take the company to new heights.
With over two and a half decades of experience in the pharmaceutical and health care industries, Mark Murray has held a variety of positions ranging from product development to commercialization. Most recently, Murray served as the Vice President of North American Technical Operations and Quality Assurance at Recordati Rare Diseases in New Jersey. Prior to that, he held esteemed positions at Cardinal Health, Lundbeck, and Ovation Pharmaceuticals in Europe and the United States. With a proven track record of success, Murray has managed R&D, operations, supply chain, and quality operations teams efficiently and effectively.
Murray has achieved quite a lot in his academic career, graduating from the University of Wales, Swansea with a B.Sc. in Biochemistry, obtaining his MBA from Seton Hall University, and earning his MS in healthcare leadership from Brown University. His hard work and dedication has been rewarded as he now holds a grand total of 87 international patents.
I am delighted to be part of Aprecia’s revolutionary culture and build on its strong foundation. Aprecia’s 3DP pharmaceutical technology offers a unique chance to address the growing demands of the global industry, including faster market entry, increased value to payors, and, most importantly, better healthcare for patients. I’m excited to collaborate with our experienced team to improve healthcare worldwide.
About Aprecia Pharmaceuticals, LLC
Aprecia, founded in 2003, is revolutionizing the pharmaceutical industry with its groundbreaking 3D printing technology. By becoming the first company to receive FDA approval for a 3D-printed prescription pharmaceutical product, they opened the door for the entire industry to explore the potential of 3D printing. Aprecia’s ZipDose® Technology creates rapidly disintegrating oral dosage forms that are easy to take, making them particularly beneficial for pediatric patients. Through their exclusive technology platform, Aprecia licenses their patented 3D printing equipment and applications to pharmaceutical partners, enabling them to expand their product lines and improve patient experience.